Two poster presentations at AAIC provide early
evidence of the value of ultra-low-field Swoop® system MR brain
images in ARIA-E detection and morphography evaluation in patients
with Alzheimer's disease
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health
technology company that has redefined brain imaging with the first
FDA-cleared portable magnetic resonance (MR) brain imaging
system—the Swoop® system—today announced the presentation of data
using the Swoop system to image patients with Alzheimer’s disease
including initial data from the CARE PMR study. The data was
presented at the 2024 Alzheimer’s Association International
Conference (AAIC) in Philadelphia from July 28 to August 1.
The CARE PMR (Capturing ARIA Risk Equitably with Portable MR)
study is a collection of data from multiple sites assessing the
clinical utility and workflow benefits of using Swoop® system
images to detect amyloid-related imaging abnormalities (ARIA) in
Alzheimer’s patients receiving amyloid-targeting therapy. These
investigator-initiated observational studies aim to provide
insights into the potential of ultra-low-field, portable MR brain
imaging to enhance care for patients with Alzheimer's disease
across many sites of care.
At the conference, researchers from Washington University in St.
Louis, a center actively enrolling patients in the CARE PMR study,
presented a poster titled "Advanced Imaging Modalities for ARIA
Detection and Treatment Efficacy Monitoring in Lecanemab Therapy
for Alzheimer's Disease: A Collaborative Prospective Study." The
poster, authored by Jude-Patrick Nnamdi Okafor, MD, et al.,
reported data on sixteen patients. Notably, one participant
exhibited "evidence of hyperintensity on FLAIR, consistent with
ARIA-E,” which was deemed “well detected at low field
strength.”
Researchers from Massachusetts General Hospital virtually
presented a poster titled "Portable, Low-field MRI for Alzheimer’s
Disease," authored by W. Taylor Kimberly, MD, PhD, et al. This
poster focused on the quantitative assessment of ultra-low-field
MRI images compared to conventional high-field MR images in
evaluating brain morphometry in Alzheimer's patients. The study
highlighted a strong agreement in volumes between conventional
high-field MR images and low-field MR images. The poster concluded,
“Given its portability and low operational cost, [low-field] MRI
holds promise as a valuable tool to diagnose [Alzheimer's disease]
and monitor its progression.”
Dr. Edmond Knopp, Vice President of Medical Affairs at
Hyperfine, commented, “The impressive image quality achieved with
our ultra-low-field MRI technology opens up the potential to
provide critical diagnostic information for patients with
Alzheimer's disease across many sites of care, including infusion
centers and clinics that currently cannot offer on-site imaging
capabilities. These posters provide early evidence that portable
MRI could transform Alzheimer's disease management.”
Access the abstracts through AAIC using the following links:
Title: Advanced Imaging Modalities for ARIA Detection and
Treatment Efficacy Monitoring in Lecanemab Therapy for Alzheimer's
Disease: A Collaborative Prospective Study Authors:
Jude-Patrick Nnamdi Okafor, MD, et al.
Title: Portable, Low-field MRI for Alzheimer’s Disease
Authors: W. Taylor Kimberly MD PhD, et al.
For more information about the Swoop® Portable MR Imaging®
system, please visit hyperfine.io.
About the Swoop® Portable MR Imaging® System
The Swoop® Portable MR Imaging® system is U.S. Food and Drug
Administration (FDA) cleared for brain imaging of patients of all
ages. It is a portable, ultra-low-field magnetic resonance imaging
device for producing images that display the internal structure of
the head where full diagnostic examination is not clinically
practical. When interpreted by a trained physician, these images
provide information that can be useful in determining a diagnosis.
The Swoop® system also has CE certification in the European Union
and UKCA certification in the United Kingdom. The Swoop® system is
commercially available in a select number of international
markets.
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health
technology company that has redefined brain imaging with the Swoop®
system—the first FDA-cleared, portable, ultra-low-field, magnetic
resonance brain imaging system capable of providing imaging at
multiple points of care. The mission of Hyperfine, Inc. is to
revolutionize patient care globally through transformational,
accessible, clinically relevant diagnostic imaging. Founded by Dr.
Jonathan Rothberg in a technology-based incubator called
4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists
developed the Swoop® system out of a passion for redefining brain
imaging methodology and how clinicians can apply accessible
diagnostic imaging to patient care. For more information, visit
hyperfine.io.
Hyperfine, Swoop, and Portable MR Imaging are registered
trademarks of Hyperfine, Inc.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. Actual results of
Hyperfine, Inc. (the “Company”) may differ from its expectations,
estimates and projections and consequently, you should not rely on
these forward-looking statements as predictions of future events.
Words such as “expect,” “estimate,” “project,” “budget,”
“forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believes,” “predicts,” “potential,” “continue,” and
similar expressions (or the negative versions of such words or
expressions) are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, the Company’s goals and commercial plans, the benefits
of the Company’s products and services, and the Company’s future
performance and its ability to implement its strategy. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the Company’s control and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: the success, cost and timing of the Company’s product
development and commercialization activities, including the degree
that the Swoop® system is accepted and used by healthcare
professionals; the impact of COVID-19 on the Company’s business;
the inability to maintain the listing of the Company’s Class A
common stock on the Nasdaq; the Company’s inability to grow and
manage growth profitably and retain its key employees; changes in
applicable laws or regulations; the inability of the Company to
raise financing in the future; the inability of the Company to
obtain and maintain regulatory clearance or approval for its
products, and any related restrictions and limitations of any
cleared or approved product; the inability of the Company to
identify, in-license or acquire additional technology; the
inability of the Company to maintain its existing or future
license, manufacturing, supply and distribution agreements and to
obtain adequate supply of its products; the inability of the
Company to compete with other companies currently marketing or
engaged in the development of products and services that the
Company is currently marketing or developing; the size and growth
potential of the markets for the Company’s products and services,
and its ability to serve those markets, either alone or in
partnership with others; the pricing of the Company’s products and
services and reimbursement for medical procedures conducted using
the Company’s products and services; the Company’s estimates
regarding expenses, revenue, capital requirements and needs for
additional financing; the Company’s financial performance; and
other risks and uncertainties indicated from time to time in
Company’s filings with the Securities and Exchange Commission,
including those under “Risk Factors” therein. The Company cautions
readers that the foregoing list of factors is not exclusive and
that readers should not place undue reliance upon any
forward-looking statements, which speak only as of the date made.
The Company does not undertake or accept any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions or circumstances
on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730063490/en/
Media Contact Shay Smith Health+Commerce
shay@healthandcommerce.com
Investor Contact Marissa Bych Gilmartin Group LLC
marissa@gilmartinir.com
Hyperfine (NASDAQ:HYPR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Hyperfine (NASDAQ:HYPR)
Historical Stock Chart
From Dec 2023 to Dec 2024
